110 completed, 10 terminated, 4 withdrawn, 3 active not recruiting. 48 Phase 1, 44 Phase 3, 30 Phase 2, 7 Phase 4.
Follow Janssen Pharmaceutical K.K.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis JNJ-77242113 - Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Active not recruiting | Janssen Pharmaceutical K.K. | 19 | 2024-02-09 | 2026-09-28 |
| A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer Erdafitinib Intravesical Delivery System - Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor | Phase 1 | Active not recruiting | Janssen Pharmaceutical K.K. | 5 | 2023-03-03 | 2026-08-28 |
| A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension Macitentan - Pulmonary Arterial Hypertension | Phase 3 | Completed | Janssen Pharmaceutical K.K. | 7 | 2022-11-14 | 2026-05-07 |
| A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants Ad26/protein preF RSV Vaccine, Placebo - Respiratory Syncytial Virus Prevention | Phase 3 | Terminated | Janssen Pharmaceutical K.K. | 2192 | 2022-04-01 | 2025-05-23 |
| A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants JNJ-75105186, Placebo - Healthy | Phase 1 | Withdrawn | Janssen Pharmaceutical K.K. | 2021-11-15 | 2025-02-03 | |
| A Study of JNJ-75220795 in Japanese Participants JNJ-75220795, Placebo - Fatty Liver | Phase 1 | Terminated | Janssen Pharmaceutical K.K. | 9 | 2021-11-08 | 2025-08-15 |
| A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants JNJ-77242113, Placebo - Healthy | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 36 | 2021-10-25 | 2025-02-03 |
| A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Ustekinumab, Placebo, Glucorticoid Taper Regimen - Takayasu Arteritis | Phase 3 | Terminated | Janssen Pharmaceutical K.K. | 14 | 2021-09-15 | 2025-04-29 |
| A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer Amivantamab - Stomach Neoplasms, Esophageal Neoplasms | Phase 2 | Terminated | Janssen Pharmaceutical K.K. | 62 | 2021-08-30 | 2024-09-19 |
| An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa X-Linked Retinitis Pigmentosa | Completed | Janssen Pharmaceutical K.K. | 15 | 2021-07-26 | 2025-04-25 | |
| A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice Ustekinumab - Ulcerative Colitis | Completed | Janssen Pharmaceutical K.K. | 137 | 2021-07-18 | 2025-04-28 | |
| A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma Talquetamab - Multiple Myeloma | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 15 | 2021-05-20 | 2025-10-01 |
| A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants JNJ-67953964, Placebo - Healthy | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 30 | 2021-04-30 | 2025-04-28 |
| A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan No intervention - Palmoplantar Pustulosis | Completed | Janssen Pharmaceutical K.K. | 276 | 2021-03-22 | 2026-02-10 | |
| A Study of Guselkumab in Participants With Systemic Sclerosis Guselkumab Dose 1, Guselkumab Dose 2, Placebo - Scleroderma, Systemic | Phase 2 | Completed | Janssen Pharmaceutical K.K. | 56 | 2021-02-24 | 2025-07-23 |
| A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma Teclistamab - Hematologic Malignancies | Phase 1 / Phase 2 | Completed | Janssen Pharmaceutical K.K. | 40 | 2021-02-22 | 2026-06-05 |
| A Study of JNJ-61393215 in Healthy Japanese Male Participants JNJ-61393215, Placebo - Healthy | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 24 | 2021-01-29 | 2025-04-28 |
| A Study of JNJ-40411813 in Healthy Japanese Male Participants JNJ-40411813, Matching Placebo - Healthy | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 39 | 2021-01-29 | 2025-04-28 |
| A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) Bedaquiline, Clarithromycin, Ethambutol - Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) | Phase 2 / Phase 3 | Completed | Janssen Pharmaceutical K.K. | 129 | 2021-01-08 | 2026-04-15 |
| Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan Apalutamide - Metastatic Castration-sensitive Prostate Cancer | Phase 4 | Unknown | Kindai University | 100 | 2020-11-06 | 2020-12-08 |
Showing 20 of 128. Sign in to see all of them.
Multiple Myeloma (10) · Schizophrenia (9) · Psoriasis (8) · Pain (7) · Alzheimer Disease (6) · Chronic Pain (6) · Hepatitis C, Chronic (6) · Neoplasms (6) · Hepatitis C (5) · Low Back Pain (4) · Recurrence (4) · Arthritis, Rheumatoid (3) · Dementia (3) · Prostatic Neoplasms (3) · Attention Deficit Disorder with Hyperactivity (2)
Fentanyl (7) · guselkumab (7) · Simeprevir (6) · Paliperidone Palmitate (5) · Ustekinumab (5) · ibrutinib (5) · Bortezomib (4) · Ribavirin (4) · Tramadol (4) · apalutamide (4) · Galantamine (3) · Prednisolone (3) · Risperidone (3) · Tapentadol (3) · daratumumab (3)
Japan (114) · South Korea (2) · Taiwan (2)
PMID 26359327, PMID 37022569, PMID 22121129, PMID 22816487, PMID 22984173, PMID 24005956, PMID 24906437, PMID 25117615, PMID 25655379, PMID 25749662, PMID 26588924, PMID 27616553, PMID 27866695, PMID 28324167, PMID 29260507, PMID 29417135, PMID 29514712, PMID 30134967, PMID 31268476, PMID 31446511, PMID 32002821, PMID 32878613, PMID 32915384, PMID 34102349, PMID 34696742, PMID 35508346, PMID 35596932, PMID 36732164, PMID 37652554, PMID 37811711, PMID 37895218, PMID 38149026, PMID 38296736, PMID 38880785, PMID 39498781, PMID 39559872, PMID 40104212, PMID 40319702, PMID 41485109, PMID 42766096
2023 (1)